Live Chat

交易 Vir Biotechnology VIR

VirBiotechnology 实时图表

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%): 开盘价

最新新闻

Frances Wang 2024 Dec 23, 16:00

SPOT stock price: Spotify stock reaches all-time highs

Stocks
Frances Wang 2024 Dec 23, 16:00

DRCT stock price today: Direct Digital Holdings spikes on high-volume move

Stocks
Frances Wang 2024 Dec 23, 16:00

Stock Market Today: Dow Jones Closes Higher for Third Consecutive Day

Stocks
GDP data
Dyogenes Diniz 2024 Dec 22, 17:00

Morning Note: GDP in the UK, Spain and Canada to Shake Markets Today

Frances Wang 2024 Dec 22, 16:00

Bitcoin ETFs Experience Record Outflows Amid Crypto Market Decline

Cryptocurrencies ETFs
Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies

信息

点差

0.06

点差(%)

0.8108 %

杠杆

1:10

隔夜利息(买入)

-0.0597 %

隔夜利息(卖出)

-0.0292 %

币种

USD

交易时间

市场关闭

星期四

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-17:59

星期五

14:31-20:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

1010864832

在外流通股份

137720000

财报日(下一)

0000-00-00

股息收益率

除息日

远期年度股息率

0

远期年股息率

0

每股收益

-3.93

详细了解此金融票据

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

相关金融票据

资产
出售
买入
更改(%):
相关金融票据
Trustpilot
Live Chat